{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T10:47:00Z","timestamp":1659091620533},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,3,10]],"date-time":"2017-03-10T00:00:00Z","timestamp":1489104000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s11255-017-1563-5","type":"journal-article","created":{"date-parts":[[2017,3,10]],"date-time":"2017-03-10T12:51:26Z","timestamp":1489150286000},"page":"1049-1056","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Combination therapy with lamivudine and angiotensin-converting enzyme inhibitor\/angiotensin receptor blocker for hepatitis B virus-associated glomerulonephritis with mild to moderate proteinuria: a clinical review of 38 cases"],"prefix":"10.1007","volume":"49","author":[{"given":"Li-Jing","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Ping","family":"Shan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruo-Lan","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Jie","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geng-Ru","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,3,10]]},"reference":[{"issue":"2","key":"1563_CR1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1046\/j.1365-2893.2003.00487.x","volume":"11","author":"D Lavanchy","year":"2004","unstructured":"Lavanchy D (2004) Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 11(2):97\u2013107","journal-title":"J Viral Hepat"},{"issue":"9","key":"1563_CR2","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.compbiomed.2013.05.021","volume":"43","author":"W Hongfei","year":"2013","unstructured":"Hongfei W, Yunyan Z, Fei Y, Hui L (2013) Evaluation of an artificial neural network to ascertain why there is a high incidence of hepatitis B in the Chinese population after vaccination. Comput Biol Me 43(9):1167\u20131170","journal-title":"Comput Biol Me"},{"issue":"10 Suppl 3","key":"1563_CR3","doi-asserted-by":"crossref","first-page":"S175","DOI":"10.1097\/00004836-200411003-00010","volume":"38","author":"G Zhiqiang","year":"2004","unstructured":"Zhiqiang G, Zhaohui D, Qinhuan W, Dexian C, Yunyun F, Hongtao L, Iloeje UH (2004) Cost of chronic hepatitis B infection in China. J Clin Gastroenterol 38(10 Suppl 3):S175\u2013S178","journal-title":"J Clin Gastroenterol"},{"issue":"1","key":"1563_CR4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/BF00868249","volume":"8","author":"RD Gilbert","year":"1994","unstructured":"Gilbert RD, Wiggelinkhuizen J (1994) The clinical course of hepatitis B virus-associated nephropathy. Pediatr Nephrol 8(1):11\u201314","journal-title":"Pediatr Nephrol"},{"issue":"21","key":"1563_CR5","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1056\/NEJM199105233242103","volume":"324","author":"KN Lai","year":"1991","unstructured":"Lai KN, Li PK, Lui SF, Au TC, Tam JS, Tong KL, Lai FM (1991) Membranous nephropathy related to hepatitis B virus in adults. N Engl J Med 324(21):1457\u20131463","journal-title":"N Engl J Med"},{"issue":"2","key":"1563_CR6","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1159\/000077065","volume":"24","author":"R Bhimma","year":"2004","unstructured":"Bhimma R, Coovadia HM (2004) Hepatitis B virus-associated nephropathy. Am J Nephrol 24(2):198\u2013211","journal-title":"Am J Nephrol"},{"issue":"1","key":"1563_CR7","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1159\/000185802","volume":"54","author":"KN Lai","year":"1990","unstructured":"Lai KN, Tam JS, Lin HJ, Lai FM (1990) The therapeutic dilemma of the usage of corticosteroid in patients with membranous nephropathy and persistent hepatitis B virus surface antigenaemia. Nephron 54(1):12\u201317","journal-title":"Nephron"},{"issue":"2","key":"1563_CR8","first-page":"161","volume":"54","author":"H Taskapan","year":"2000","unstructured":"Taskapan H, Oymak O, Dogukan A, Ozbakir O, Utas C (2000) Transformation of hepatitis B virus-related membranous glomerulonephritis to crescentic form. Clin Nephrol 54(2):161\u2013163","journal-title":"Clin Nephrol"},{"issue":"2","key":"1563_CR9","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S1665-2681(19)31565-0","volume":"10","author":"Z Yi","year":"2011","unstructured":"Yi Z, Jie YW, Nan Z (2011) The efficacy of anti-viral therapy on hepatitis B virus-associated glomerulonephritis: a systematic review and meta-analysis. Ann Hepatol 10(2):165\u2013173","journal-title":"Ann Hepatol"},{"issue":"9","key":"1563_CR10","first-page":"530","volume":"29","author":"WZ Zhou","year":"1990","unstructured":"Zhou WZ, Zhang WL, Geng L (1990) Glomerulonephropathy associated with hepatitis B virus (HBV) infection. Zhonghua Nei Ke Za Zhi 29(9):530\u2013533","journal-title":"Zhonghua Nei Ke Za Zhi"},{"issue":"3","key":"1563_CR11","first-page":"763","volume":"16","author":"M Froissart","year":"2005","unstructured":"Froissart M, Rossert J, Jacquot C, Paillard M, Houillier P (2005) Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function. J Am SocNephrol 16(3):763\u2013773","journal-title":"J Am SocNephrol"},{"issue":"2 Suppl 1","key":"1563_CR12","first-page":"S1","volume":"39","author":"National Kidney Foundation","year":"2002","unstructured":"National Kidney Foundation (2002) K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39(2 Suppl 1):S1\u2013S266","journal-title":"Am J Kidney Dis"},{"key":"1563_CR13","volume-title":"Renal disease: classification and atlas of glomerular disease","author":"JBJ Churg","year":"1995","unstructured":"Churg JBJ, Glassock RJ (1995) Renal disease: classification and atlas of glomerular disease. Ikagu-Shoin, New York"},{"issue":"4","key":"1563_CR14","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jhep.2007.07.006","volume":"47","author":"ZD Goodman","year":"2007","unstructured":"Goodman ZD (2007) Grading and staging systems for inflammation and fibrosis in chronic liver diseases. J Hepatol 47(4):598\u2013607","journal-title":"J Hepatol"},{"issue":"4","key":"1563_CR15","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1111\/j.1523-1755.2005.00591.x","volume":"68","author":"S Tang","year":"2005","unstructured":"Tang S, Lai FM, Lui YH, Tang CS, Kung NN, Ho YW, Chan KW, Leung JC, Lai KN (2005) Lamivudine in hepatitis B-associated membranous nephropathy. Kidney Int 68(4):1750\u20131758","journal-title":"Kidney Int"},{"issue":"3","key":"1563_CR16","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1006\/jaut.2000.0502","volume":"16","author":"C Trepo","year":"2001","unstructured":"Trepo C, Guillevin L (2001) Polyarteritis nodosa and extrahepatic manifestations of HBV infection: the case against autoimmune intervention in pathogenesis. J Autoimmun 16(3):269\u2013274","journal-title":"J Autoimmun"},{"issue":"2","key":"1563_CR17","first-page":"101","volume":"4","author":"H Khedmat","year":"2010","unstructured":"Khedmat H, Taheri S (2010) Hepatitis B\u00a0virus-associated\u00a0nephropathy: an international data analysis. Iran J Kidney Dis 4(2):101\u2013105","journal-title":"Iran J Kidney Dis"},{"issue":"5 Suppl","key":"1563_CR18","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1002\/hep.22881","volume":"49","author":"TJ Liang","year":"2009","unstructured":"Liang TJ (2009) Hepatitis B: the virus and disease. Hepatology 49(5 Suppl):S13\u2013S21","journal-title":"Hepatology"},{"issue":"2","key":"1563_CR19","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000184477","volume":"47","author":"KN Lai","year":"1987","unstructured":"Lai KN, Lai FM, Lo S, Ho CP, Chan KW (1987) IgA nephropathy associated with hepatitis B virus antigenemia. Nephron 47(2):141\u2013143","journal-title":"Nephron"},{"issue":"4","key":"1563_CR20","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0046-8177(87)80177-6","volume":"18","author":"KN Lai","year":"1987","unstructured":"Lai KN, Lai FM, Lo ST, Lam CW (1987) IgA nephropathy and membranous nephropathy associated with hepatitis B surface antigenemia. Hum Pathol 18(4):411\u2013414","journal-title":"Hum Pathol"},{"issue":"4","key":"1563_CR21","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/path.1711570409","volume":"157","author":"KN Lai","year":"1989","unstructured":"Lai KN, Lai FM, Tam JS (1989) IgA nephropathy associated with chronic hepatitis B virus infection in adults: the pathogenetic role of HBsAG. J Pathol 157(4):321\u2013327","journal-title":"J Pathol"},{"issue":"9","key":"1563_CR22","doi-asserted-by":"crossref","first-page":"885","DOI":"10.3109\/0886022X.2011.605979","volume":"33","author":"X Li","year":"2011","unstructured":"Li X, Huang A, Zhou P, Dang X, Mo S, Yi Z, He Q (2011) Differences in tissue expression of HBV markers in children with HBV-associated glomerulonephritis. Ren Fail 33(9):885\u2013891","journal-title":"Ren Fail"},{"issue":"6","key":"1563_CR23","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1097\/01.ASN.0000068460.37369.DC","volume":"14","author":"M Praga","year":"2003","unstructured":"Praga M, Gutierrez E, Gonzalez E, Morales E, Hernandez E (2003) Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol 14(6):1578\u20131583","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"1563_CR24","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s10157-008-0040-y","volume":"12","author":"Y Tamura","year":"2008","unstructured":"Tamura Y, Kosuga M, Yamashita M, Tomioka S, Sasaki M, Hikita T, Nakajima H, Kojima K, Uchida S (2008) Renoprotective effects of angiotensin II receptor blocker, candesartan cilexetil, in patients with stage 4\u20135 chronic kidney disease. Clin Exp Nephrol 12(4):256\u2013263","journal-title":"Clin Exp Nephrol"},{"issue":"1","key":"1563_CR25","doi-asserted-by":"crossref","first-page":"21","DOI":"10.5414\/CN108648","volume":"85","author":"WN Wang","year":"2016","unstructured":"Wang WN, Wu MY, Ma FZ, Sun T, Xu ZG (2016) Meta-analysis of the efficacy and safety of nucleotide\/nucleoside analog monotherapy for\u00a0hepatitis B virus-associated glomerulonephritis. Clin Nephrol 85(1):21\u201329","journal-title":"Clin Nephrol"},{"issue":"1","key":"1563_CR26","doi-asserted-by":"crossref","first-page":"c41","DOI":"10.1159\/000324652","volume":"119","author":"U Elewa","year":"2011","unstructured":"Elewa U, Sandri AM, Kim WR, Fervenza FC (2011) Treatment of hepatitis B virus-associated nephropathy. Nephron Clin Pract 119(1):c41\u2013c49","journal-title":"Nephron Clin Pract"},{"issue":"3","key":"1563_CR27","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12072-008-9080-3","volume":"2","author":"YF Liaw","year":"2008","unstructured":"Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK, Locarnini S, Chronic Hepatitis B Guideline Working Party of the Asian-Pacific Association for the Study of the Liver (2008) Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2(3):263\u2013283","journal-title":"Hepatol Int"},{"issue":"5","key":"1563_CR28","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1016\/j.clinre.2012.03.033","volume":"36","author":"YF Yang","year":"2012","unstructured":"Yang YF, Xiong QF, Zhao W, Zhong YD (2012) Complete remission of hepatitis B virus-related membranous nephropathy after entecavir monotherapy. Clin Res Hepatol Gastroenterol 36(5):e89\u2013e92","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"4","key":"1563_CR29","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3904\/kjim.2012.27.4.411","volume":"27","author":"IO Sun","year":"2012","unstructured":"Sun IO, Hong YA, Park HS, Choi SR, Chung BH, Park CW, Yang CW, Kim YS, Choi BS (2012) Experience of anti-viral therapy in hepatitis B-associated membranous nephropathy, including Lamivudine-resistant strains. Korean J Intern Med 27(4):411\u2013416","journal-title":"Korean J Intern Med"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11255-017-1563-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-017-1563-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-017-1563-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T15:40:27Z","timestamp":1568907627000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11255-017-1563-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,10]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["1563"],"URL":"https:\/\/doi.org\/10.1007\/s11255-017-1563-5","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,10]]}}}